Related Experiment Videos

ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation

D Y Huang1, K H Weisgraber, M Goedert

  • 1Department of Medicine (Neurology), Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710, USA.

Neuroscience Letters
|June 16, 1995
PubMed

Insights

Apolipoprotein E (ApoE) interactions with tau protein differ by ApoE type, influencing Alzheimer's disease risk. Understanding these specific binding mechanisms is key for developing new therapeutic strategies.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Alzheimer's disease (AD) risk is linked to apolipoprotein E (ApoE) alleles.
  • ApoE interacts with tau protein, a component of neurofibrillary tangles in AD.

Purpose of the Study:

  • To investigate the isoform-specific binding of ApoE to tau protein.
  • To understand how tau phosphorylation affects ApoE binding.

Main Methods:

  • Used synthetic peptides representing tau's microtubule-binding domains.
  • Assessed binding avidity of ApoE3 and ApoE4 to these tau peptides.
  • Examined the effect of tau phosphorylation at serine262 on ApoE binding.

Main Results:

  • ApoE3 showed higher binding avidity to tau peptides than ApoE4.
  • Phosphorylation of tau at serine262 reduced tau's binding to microtubules.
  • Phosphorylation at serine262 abolished ApoE3 binding to tau.

Conclusions:

  • ApoE isoform-specific interactions with tau are significant in Alzheimer's disease.
  • Tau phosphorylation at serine262 disrupts ApoE binding, impacting disease mechanisms.
  • Further research into these molecular interactions may guide AD interventions.

Related Concept Videos